Get the Stockscreener App
6.94
0.14%
0.01
After Hours:
6.92
-0.02
-0.29%
Emergent Biosolutions Inc stock is traded at $6.94, with a volume of 682.29K.
It is up +0.14% in the last 24 hours and up +11.58% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
See More
Previous Close:
$6.93
Open:
$7.01
24h Volume:
682.29K
Relative Volume:
0.55
Market Cap:
$376.69M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.4702
EPS:
-14.76
Net Cash Flow:
$-257.90M
1W Performance:
-4.93%
1M Performance:
+11.58%
6M Performance:
-32.09%
1Y Performance:
-38.04%
1-Day Range:
$6.89
$7.16
1-Week Range:
$6.74
$7.43
52-Week Range:
$4.02
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
6.94 | 396.23M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
147.37 | 69.30B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 47.50B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.53 | 44.47B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.31 | 18.83B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
293.12 | 13.43B | 2.99B | 1.21B | 1.13B | 25.06 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
What drives Emergent BioSolutions Inc. stock priceHigh-octane gains - Autocar Professional
Emergent BioSolutions Inc. Stock Analysis and ForecastFree Investment Community - PrintWeekIndia
Is Emergent BioSolutions Inc. a good long term investmentMassive portfolio appreciation - PrintWeekIndia
Is MDU Resources Group Inc. a good long term investmentHigh-yield investments - jammulinksnews.com
AGYS Stock Analysis and ForecastAccelerated financial growth - Autocar Professional
What analysts say about Emergent BioSolutions Inc. stockFree Investment Community - jammulinksnews.com
Hawthorn Bancshares Inc. Stock Analysis and ForecastBreakthrough capital growth - jammulinksnews.com
What drives EMX Royalty Corporation stock priceSkyrocketing returns - jammulinksnews.com
Emergent Signs $174M Manufacturing Deal For AstraZeneca’s Covid-19 Candidate - TipRanks
What makes Emergent BioSolutions Inc. stock price move sharplyPotential Rocket List - beatles.ru
Lobbying Update: $440,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Nasdaq
Emergent BioSolutions to Report Second Quarter 2025 Financial Re - GuruFocus
Emergent BioSolutions Inc. to Host Q2 2025 Financial Results Conference Call on August 6 - Nasdaq
Emergent BioSolutions Q2 2025 Earnings Call Scheduled for August 6: Key Details Inside - Stock Titan
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 - TradingView
Government Contract Update: $52M payment to EMERGENT BIOSOLUTIONS CANADA INC - Nasdaq
Emergent BioSolutions signs contract modification award for CNJ-016 - MSN
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Benchmark Co. Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts - The Manila Times
Emergent BioSolutions Stock Rises After New US Order For Smallpox Complication Therapy - Stocktwits
Emergent BioSolutions secures contract modification for smallpox treatment By Investing.com - Investing.com South Africa
Emergent BioSolutions secures contract modification for smallpox treatment - Investing.com Australia
Emergent BioSolutions (EBS) Expands Smallpox Vaccine Contract wi - GuruFocus
Emergent BioSolutions (EBS) Secures Smallpox Preparedness Contra - GuruFocus
Emergent BioSolutions Gets $51.9 Million Contract Modification for Smallpox Preparedness - MarketScreener
Emergent BioSolutions stock rises on government contract modification By Investing.com - Investing.com Canada
Emergent BioSolutions stock rises on government contract modification - Investing.com India
Emergent BioSolutions Secures Contract Modification for Additional VIGIV Doses to Support U.S. Smallpox Preparedness - Quiver Quantitative
Emergent BioSolutions Strengthens US Biodefense Arsenal with $51.9M Government Contract - Stock Titan
Emergent BioSolutions Secures $51.9 Million Contract Modificatio - GuruFocus
Lobbying Update: $40,000 of EMERGENT BIOSOLUTIONS lobbying was just disclosed - Quiver Quantitative
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way? - simplywall.st
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate - The Manila Times
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® ( - GuruFocus
Emergent BioSolutions adds KLOXXADO to online naloxone platform By Investing.com - Investing.com UK
Investors Can Still File Late Claims in Emergent BioSolutions Settlement - TradingView
Emergent BioSolutions Inc.(NYSE: EBS) added to Russell 3000E Value Index - MarketScreener
Is Emergent BioSolutions, Inc. overvalued or undervalued? - MarketsMojo
Emergent BioSolutions secures $62.4 million contract for botulism antitoxin By Investing.com - Investing.com South Africa
Emergent BioSolutions Awarded $62.4 Million Contract Modification for BAT® Antitoxin by U.S. Department of Health and Human Services - Quiver Quantitative
Emergent BioSolutions Announces Addition to Russell 3000® Index - The Manila Times
Emergent BioSolutions to join Russell 3000 Index after market close June 27 - Investing.com Nigeria
EBS Stock Up 1.4% after 1-Day Win Streak - Trefis
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030 - GlobeNewswire
Government Contract Update: $62M payment to EMERGENT BIOSOLUTIONS CANADA INC - Nasdaq
BRIEF—LigaChem links up with NovaRock - The Pharma Letter
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact Its Attorneys Now, Securities Fraud Case Pending, Firm Investigating CEO’s Insider Sales - ACCESS Newswire
Emergent BioSolutions at Jefferies Conference: Strategic Transformation By Investing.com - Investing.com Canada
Squarepoint Ops LLC Has $451,000 Stake in Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Emergent BioSolutions (EBS) Partners with Foundation for Opioid Awareness | EBS Stock News - GuruFocus
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):